Table 1.
Demographic and Clinical Characteristics of the Study Cohort
| Characteristic | Total Cohort (n = 93) | HIV-Seronegative Group |
HIV-Seropositive Group |
||
|---|---|---|---|---|---|
| Men (n = 11) | Women (n = 28) | Men (n = 20) | Women (n = 34) | ||
| Age, y | 36 (18–67) | 30 (18–48) | 28 (19–58) | 40 (26–67) | 39 (25–56) |
| Male sex | 31 (33) | 11 (100) | … | 20 (100) | … |
| Ugandan nationality | 90 (97) | 10 (91) | 28 (100) | 19 (95) | 33 (97) |
| HIV seropositivity | 54 (58) | … | … | 20 (100) | 34 (100) |
| CD4+ T-cell count, cells/mm3, median (IQR)a | 502 (291–681) | … | … | 292 (245–535) | 582 (442–724) |
| HIV RNA load, log10 copies/mL, median (IQR)a,b | 4.8 (4.0–5.2) | … | … | 5.0 (4.5–5.2) | 4.7 (3.7–5.1) |
| Male circumcision | 10 (32) | 4 (36) | … | 6 (30) | … |
| Hormonal contraception | 26 (42) | … | 15 (54) | … | 11 (32) |
| Age at first sex, y | 17 (10–25) | 17 (14–25) | 17 (13–23) | 18 (10–25) | 17 (13–21) |
| HSV antibody status | |||||
| HSV type 2 only | 4 (4) | 1 (9) | 0 (0) | 0 (0) | 3 (9) |
| HSV types 1 and 2 | 89 (96) | 10 (91) | 28 (100) | 20 (100) | 31 (91) |
| History of genital herpes symptoms | 80 (86) | 9 (82) | 23 (82) | 17 (85) | 31 (91) |
| Time from first genital herpes episode to enrollment, yc | 2.5 (0.1–36.6) | 2.2 (0.3–16.8) | 1.7 (0.1–34.6) | 5.0 (0.1–26.6) | 2.0 (0.1–36.6) |
Data are median value (range) or no. (%) of subjects, unless otherwise indicated.
Abbreviations: HIV, human immunodeficiency virus type 1; HSV, herpes simplex virus; IQR, interquartile range.
a Among HIV-seropositive subjects.
b Measured only for those with detectable plasma HIV RNA.
c Among those reporting a history of genital herpes symptoms.